Randomized Phase II Study of Docetaxel plus Bevacizumab or Pemetrexed plus Bevacizumab for Elderly Non-Squamous NSCLC (TORG1323)

被引：0
|
作者：
Kozuki, Toshiyuki [1 ]
Nogami, Naoyuki [1 ]
Yamashita, Natsumi [2 ]
Shinkai, Tetsu [3 ]
Shukuya, Takehito [4 ,5 ]
Seki, Nobuhiko [6 ]
Kato, Terufumi [7 ]
Satouchi, Miyako [8 ]
Masuda, Noriyuki [9 ]
Watanabe, Koshiro [10 ]
机构：
[1] Natl Hosp Org, Shikoku Canc Ctr, Dept Thorac Oncol & Med, Matsuyama, Ehime, Japan
[2] Natl Hosp Org, Shikoku Canc Ctr, Clin Res Ctr, Matsuyama, Ehime, Japan
[3] Shonan East Gen Hosp, Dept Internal Med, Chigasaki, Kanagawa, Japan
[4] Juntendo Univ, Fac Med, Div Resp Med, Tokyo, Japan
[5] Grad Sch Med, Tokyo, Japan
[6] Teikyo Univ, Sch Med, Dept Med Oncol, Tokyo 173, Japan
[7] Kanagawa Cardiovasc & Resp Ctr, Resp Med, Yokohama, Kanagawa, Japan
[8] Hyogo Canc Ctr, Dept Thorac Oncol, Akashi, Hyogo, Japan
[9] Kitasato Univ, Sch Med, Dept Resp Med, Kanagawa, Japan
[10] Thorac Oncol Res Grp, Yokohama, Kanagawa, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
elderly; Clinical Trial in Progress; NSCLC; bevacizumab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.01-085
引用
收藏
页码：S666 / S666
页数：1
相关论文
共 50 条
  • [41] Randomized, Double-Blind, Phase 3 Study Comparing Biosimilar Candidate ABP 215 with Bevacizumab in Patients with Non-Squamous NSCLC
    Thatcher, Nick
    Thomas, Michael
    Ostoros, Gyula
    Pan, Jean
    Goldschmidt, Jerome
    Schenker, Michael
    Hanes, Vladimir
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S902 - S903
  • [42] Prospective phase II study of cisplatin plus pemetrexed with maintenance of pemetrexed for advanced non-squamous cell non-small cell lung cancer in Japan
    Asami, Kazuhiro
    Kawahara, Masaaki
    Hirashima, Tomonori
    Suzuki, Hidekazu
    Okishio, Kyoichi
    Omachi, Naoki
    Tamiya, Motohiro
    Tamiya, Akihiro
    Hirooka, Aya
    Nakao, Keiko
    Tsuji, Taisuke
    Atagi, Shinji
    THORACIC CANCER, 2014, 5 (04) : 289 - 296
  • [43] Pemetrexed, Carboplatin and Bevacizumab in Patients with Non-Squamous NSCLC without or with Activating EGFR Mutation (CJLSG0909/0910)
    Kimura, Tomoki
    Taniguchi, Hiroyuki
    Ogasawara, Tomohiko
    Kondo, Masashi
    Takeyama, Yoshihiro
    Yamamoto, Masashi
    Shindoh, Joe
    Hataji, Osamu
    Yoshida, Norio
    Kojima, Eiji
    Imaizumi, Kazuyoshi
    Tanikawa, Yoshimasa
    Yamada, Yoshiyuki
    Ikeda, Takuya
    Ichikawa, Motoshi
    Hasegawa, Yoshinori
    Saito, Hiroshi
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S548 - S549
  • [44] Phase II study of S-1 plus bevacizumab combination therapy for patients previously treated for non-squamous non-small cell lung cancer
    Yu Nishijima-Futami
    Seigo Minami
    Shinji Futami
    Taro Koba
    Masayoshi Higashiguchi
    Motohiro Tamiya
    Hidekazu Suzuki
    Tomonori Hirashima
    Kiyoshi Komuta
    Takashi Kijima
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 1215 - 1220
  • [45] Phase II Study of S-1 plus Bevacizumab Combination Therapy for Patients Previously Treated for Non-Squamous Non-Small Cell Lung Cancer
    Masuhiro, K.
    Nishijima-Futami, Y.
    Minami, S.
    Futami, S.
    Koba, T.
    Higashiguchi, M.
    Tamiya, M.
    Suzuki, H.
    Hirashima, T.
    Komuta, K.
    Kijima, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1968 - S1968
  • [46] Phase II study of S-1 plus bevacizumab combination therapy for patients previously treated for non-squamous non-small cell lung cancer
    Nishijima-Futami, Yu
    Minami, Seigo
    Futami, Shinji
    Koba, Taro
    Higashiguchi, Masayoshi
    Tamiya, Motohiro
    Suzuki, Hidekazu
    Hirashima, Tomonori
    Komuta, Kiyoshi
    Kijima, Takashi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (06) : 1215 - 1220
  • [47] A phase II study of metformin plus pemetrexed and carboplatin in patients with non-squamous non-small cell lung cancer (METALUNG)
    Verma, S.
    Chitikela, S.
    Singh, V.
    Khurana, S.
    Pushpam, D.
    Jain, D.
    Kumar, S.
    Gupta, Y.
    Malik, P. S.
    MEDICAL ONCOLOGY, 2023, 40 (07)
  • [48] Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
    G L Ceresoli
    P A Zucali
    M Mencoboni
    M Botta
    F Grossi
    D Cortinovis
    N Zilembo
    C Ripa
    M Tiseo
    A G Favaretto
    H Soto-Parra
    F De Vincenzo
    A Bruzzone
    E Lorenzi
    L Gianoncelli
    B Ercoli
    L Giordano
    A Santoro
    British Journal of Cancer, 2013, 109 : 552 - 558
  • [49] Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
    Ceresoli, G. L.
    Zucali, P. A.
    Mencoboni, M.
    Botta, M.
    Grossi, F.
    Cortinovis, D.
    Zilembo, N.
    Ripa, C.
    Tiseo, M.
    Favaretto, A. G.
    Soto-Parra, H.
    De Vincenzo, F.
    Bruzzone, A.
    Lorenzi, E.
    Gianoncelli, L.
    Ercoli, B.
    Giordano, L.
    Santoro, A.
    BRITISH JOURNAL OF CANCER, 2013, 109 (03) : 552 - 558
  • [50] A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer
    Motohiro Tamiya
    Akihiro Tamiya
    Hiroyasu Kaneda
    Kazuhiko Nakagawa
    Kiyotaka Yoh
    Koichi Goto
    Hiroaki Okamoto
    Tsuneo Shimokawa
    Tetsuya Abe
    Hiroshi Tanaka
    Haruko Daga
    Koji Takeda
    Tomonori Hirashima
    Shinji Atagi
    Medical Oncology, 2016, 33
12345